|
Daily Medical Update
H. pylori (Test-and-treat, bismuth quadruple)
Sunday, March 22, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
The Turkish Journal of Gastroenterology (2026) - Prospective Non-inferiority Cohort
Key Findings
- Eradication by intention-to-treat was comparable with vonoprazan once daily versus twice daily in bismuth quadruple therapy (89.2% vs 88.9%).
- Per-protocol cure rates were similarly high (92.2% vs 95.2%) with no significant efficacy loss at once-daily dosing.
- Adverse-event rates were low and similar (8.9% vs 12.0%), while cost-effectiveness favored once-daily dosing.
📋 Practice Implication: If using vonoprazan-based bismuth quadruple therapy, once-daily vonoprazan is a practical option to reduce cost and pill burden while maintaining high expected eradication rates.
|
United European Gastroenterology Journal (2026) - Population-Based Program Study
Key Findings
- In serology-positive participants, confirmatory breath testing was positive in 83.7%, refining true treatment candidates.
- A 14-day bismuth-based quadruple regimen achieved 94.7% eradication (95% CI 89.5-97.9) in this community implementation.
- Adverse events were acceptable overall but occurred more often in women than men (38.8% vs 21.5%).
📋 Practice Implication: A PCP-led screen-and-treat pathway can be effective when confirmatory testing is used and counseling anticipates sex-specific tolerability differences that may affect persistence.
|
Journal of Gastroenterology and Hepatology (2026) - Meta-analysis
Key Findings
- Across 3667 participants, semisynthetic tetracycline-containing quadruple regimens improved per-protocol eradication versus controls (91.8% vs 85.6%; OR 1.47).
- Overall adverse events were reduced with semisynthetic tetracycline regimens (32.0% vs 39.2%; OR 0.73).
- Subgroup analyses showed improved eradication with 14-day courses (92.3% vs 88.5%) and better outcomes with doxycycline-containing protocols (82.6% vs 71.8%).
📋 Practice Implication: Where classic tetracycline access is limited, doxycycline or other semisynthetic tetracycline-containing quadruple regimens are evidence-supported substitutions, especially over a 14-day course.
|
Arab Journal of Gastroenterology (2026) - Prospective Randomized Study
Key Findings
- First-line eradication rates were similar between bismuth quadruple (79.5%) and concomitant quadruple therapy (76.1%) with no significant difference.
- Overall adverse-event burden was comparable, but diarrhea increased with concomitant therapy while bismuth therapy increased stool discoloration.
- Treatment completion exceeded 93% in both regimens, demonstrating similarly high real-world regimen tolerability and execution across arms.
📋 Practice Implication: When selecting empiric first-line quadruple therapy, tailor to local resistance context and patient tolerance priorities rather than expecting large efficacy differences between these two regimens.
|
Journal of Medical Microbiology (2026) - Reference Laboratory Observational Study
Key Findings
- Among mostly refractory cases, resistance rates were very high for metronidazole (96.1%) and clarithromycin (82.2%), with substantial levofloxacin resistance (31.5%).
- Resistance remained low to amoxicillin (1.2%) and tetracycline (0.2%), supporting their continued value in regimen design.
- Culture recovery declined sharply with transport delays, dropping below 35% when biopsy transit exceeded 4 days.
📋 Practice Implication: For retreatment and recurrent failure, prioritize regimens anchored by low-resistance agents and expedite specimen transport when susceptibility testing is planned, because delayed culture can forfeit actionable guidance.
|
The Korean Journal of Helicobacter and Upper Gastrointestinal Research (2026) - Evidence Review
Key Findings
- Clarithromycin-containing triple therapy first-line eradication has dropped below 70% alongside clarithromycin resistance above 30%.
- Evidence synthesis supports a shift toward quadruple empiric regimens and PCR-guided tailored strategies with first-line cure rates reported at or above 90% in domestic data.
- Bismuth quadruple therapy improved second-line eradication positioning and is retained as the standard salvage anchor in the updated sequencing.
📋 Practice Implication: In practices facing rising macrolide resistance, retire routine clarithromycin triple therapy and align with quadruple-first or resistance-guided treatment algorithms.
|
|
Recent evidence supports bismuth-based and other quadruple approaches as the practical backbone for H. pylori eradication in the setting of persistent resistance to legacy triple therapy. New comparative and population-level data show high cure rates are achievable with appropriately selected 10- to 14-day quadruple regimens, and regimen optimization (including acid suppression strategy and tetracycline substitutions) can improve feasibility without major efficacy tradeoffs. For PCP practice, the major signal is to favor resistance-aware regimen selection and strengthen adherence/tolerability support rather than relying on clarithromycin triple therapy in higher-resistance settings.
|
|